Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW)

被引：0
|
作者：
Shitara, Kohei
Xu, Rui-Hua
Moran, Diarmuid Martin
Guerrero, Abraham
Li, Ran
Pavese, Janet
Matsangou, Maria
Bhattacharya, Pranob P.
Ajani, Jaffer A.
Shah, Manish A.
机构：
[1] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[2] Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[3] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[4] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Gastrointestinal Med Oncol, Houston, TX USA
[5] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4035
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
    Shitara, Kohei
    Xu, Rui-Hua
    Ajani, Jaffer A.
    Moran, Diarmuid
    Guerrero, Abraham
    Li, Ran
    Pavese, Janet
    Matsangou, Maria
    Bhattacharya, Pranob
    Ueno, Yoko
    Wang, Xuewei
    Shah, Manish A.
    GASTRIC CANCER, 2024, 27 (05) : 1058 - 1068
  • [22] ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
    Klempner, Samuel J.
    Lee, Keun-Wook
    Shitara, Kohei
    Metges, Jean-Phillippe
    Lonardi, Sara
    Ilson, David H.
    Fazio, Nicola
    Kim, Tae Yong
    Bai, Li-Yuan
    Moran, Diarmuid
    Yang, Jianning
    Arozullah, Ahsan
    Park, Jung Wook
    Raizer, Jeffrey J.
    Bang, Yung-Jue
    Shah, Manish A.
    CLINICAL CANCER RESEARCH, 2023, 29 (19) : 3882 - 3891
  • [23] Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Ajani, J. A.
    Lordick, F.
    Bang, Y-J.
    Enzinger, P. C.
    Ilson, D. H.
    Shah, M. A.
    van Cutsem, E.
    Xu, R-H.
    Aprile, G.
    Xu, J.
    Pazo Cid, R. A.
    Kang, Y-K.
    Yang, J.
    Moran, D.
    Bhattacharya, P.
    Matsangou, M.
    Arozullah, A.
    Park, J. W.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1524 - S1525
  • [24] Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.
    Klempner, Samuel J.
    Lee, Keun-Wook
    Metges, Jean-Philippe
    Catenacci, Daniel V. T.
    Loupakis, Fotios
    Ilson, David H.
    Shah, Manish A.
    Shitara, Kohei
    Arozullah, Ahsan
    Park, Jung Wook
    Raizer, Jeffrey J.
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Ajani, J. A.
    Lordick, F.
    Bang, Y-J.
    Enzinger, P. C.
    Ilson, D. H.
    Shah, M. A.
    Van Cutsem, E.
    Xu, R-H.
    Aprile, G.
    Xu, J.
    Cid, R. A. Pazo
    Kang, Y-K.
    Yang, J.
    Moran, D.
    Bhattacharya, P.
    Matsangou, M.
    Arozullah, A.
    Park, J. W.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1322 - S1322
  • [26] Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Lordick, F.
    Shah, M. A.
    Shitara, K.
    Ajani, J. A.
    Bang, Y-J.
    Enzinger, P. C.
    Ilson, D. H.
    Van Cutsem, E.
    Plazas, J. Gallego
    Huang, J.
    Shen, L.
    Oh, S. C.
    Sunpaweravong, P.
    Soo, H. H. F.
    Turk, H. M.
    Park, J. W.
    Moran, D.
    Bhattacharya, P.
    Cao, Y. J.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1321 - S1321
  • [27] Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Lordick, F.
    Shah, M. A.
    Shitara, K.
    Ajani, J. A.
    Bang, Y-J.
    Enzinger, P. C.
    Ilson, D. H.
    van Cutsem, E.
    Gallego Plazas, J.
    Huang, J.
    Shen, L.
    Oh, S. C.
    Sunpaweravong, P.
    Soo, H. H. F.
    Turk, H. M.
    Park, J. W.
    Moran, D.
    Bhattacharya, P.
    Cao, Y. J.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1524 - S1524
  • [28] Real-world practices and physician perspectives on biomarker testing and treatment patterns in patients with locally advanced unresectable or metastatic (La/m) gastric/gastroesophageal junction (G/GEJ) adenocarcinoma in the US
    Lewis, K.
    Fuldeore, R.
    Braun, S.
    Gourgioti, G.
    Lambert, A.
    Thomason, G.
    Bernacki, K.
    Yang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S245 - S245
  • [29] Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro- oesophageal junction adenocarcinoma (SPOTLIGHT) : a multicentre, randomised, double-blind, phase 3 trial
    Shitara, Kohei
    Lordick, Florian
    Bang, Yung-Jue
    Enzinger, Peter
    Ilson, David
    Shah, Manish A.
    Van Cutsem, Eric
    Xu, Rui-Hua
    Aprile, Giuseppe
    Xu, Jianming
    Chao, Joseph
    Pazo-Cid, Roberto
    Kang, Yoon-Koo
    Yang, Jianning
    Moran, Diarmuid
    Bhattacharya, Pranob
    Arozullah, Ahsan
    Park, Jung Wook
    Oh, Mok
    Ajani, Jaffer A.
    LANCET, 2023, 401 (10389): : 1655 - 1668
  • [30] GLOW: Phase III study of first-line zolbetuximab plus CAPOX versus placebo plus CAPOX in Claudin18.2./HER2- advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
    Xu, R-H.
    Ajani, J. A.
    Al-Batran, S-E.
    Bang, Y-J.
    Catenacci, D.
    Enzinger, P. C.
    Ilson, D. H.
    Kim, S.
    Lordick, F.
    Shitara, K.
    van Cutsem, E.
    Arozullah, A.
    Park, J. W.
    Shah, M. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1315 - S1316
12345